Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Antisoma licenses pemtumomab to Abbott, later opts out

Executive Summary

Abbott Laboratories has licensed worldwide exclusive development and marketing rights from UK cancer biopharmaceutical company Antisoma to its late-stage ovarian cancer drug candidate Theragyn. The deal is potentially worth $110mm, mostly from milestones.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

UsernamePublicRestriction

Register